Drug Delivery Systems (DDS) Global Market – Forecast To 2027
| Publishing Date : | July, 2021 |
| Report Code : | HCPH0115 |
| Price: |
Single license $4,950
Site license $6,750 Global license $9,000 |
Drug Delivery Systems (DDS) are the advanced formulations or technologies that modulate the release profile of therapeutic or prophylactic agents, their absorption, distribution and elimination characteristics to achieve the desired therapeutic effect and enhance the safety profile, patient convenience and compliance to medications or vaccines. The drug delivery systems integrated into the drug dosage formulations control the drug release kinetics, duration of drug action, site of drug action and the concentration profile or bioavailability of the drug. The necessity to address the various challenges in delivery needs attributed to the expansion of therapeutic modalities from the primary class of small molecules to the current new generation of therapeutics, namely the highly varied and complex biotherapeutics, the need to overcome the limitations of the free or conventional active therapeutic or prophylactic moiety and to protect them or enable them to overcome the intrinsic harsh biological environment to induce their potential therapeutic or prophylactic effect are boosting the drug delivery systems market growth.
As estimated by IQ4I analysis, drug delivery systems global market is expected to reach $158,006.4 million by 2027 growing at a mid single digit CAGR from 2020 to 2027 due to escalating necessity of targeted and controlled drug delivery systems to increase the therapeutic efficiency and safety profile of medications, need for efficient biologics delivery systems, requirement of novel drug delivery systems for satisfying the therapeutic variations of elderly and pediatric population, increasing R&D expenditure of innovator pharma or biopharma companies and their cost-efficient patent ever-greening strategy either through incremental innovation or through repurposing of drugs by using novel drug delivery systems, the vast drug delivery technology enhanced product pipeline, the trend of acquisitions and collaboration agreements in the drug delivery system industry and persistently increasing prevalence of infectious and non-infectious diseases in need of better, efficient and safer prophylactics and therapeutics.
The drug delivery systems global market is categorized into various market segments based on the Route of administration, Product, drug molecule type, mechanism, application and geography. Based on the route of administration, the drug delivery systems market is segmented into oral drug delivery systems, parenteral drug delivery systems, topical drug delivery systems and pulmonary or inhalation drug delivery systems. Among these, oral drug delivery systems is the largest and fastest emerging drug delivery systems segment and is expected to grow at a mid single digit CAGR during the forecasted period due to the increasing adoption of oral drug delivery technology enhanced drug products by the value-centric patients across the globe and the elevating inclination of patients especially the geriatric and pediatric patients towards the most convenient, easier, self-administratable, painless and non-invasive drug delivery route.
The drug delivery systems market, based on product has been classified as Lipid based drug delivery systems (LBDDS) consisting of lipid emulsion drug delivery systems, lipid vesicular drug delivery systems (classified further as liposomes and other vesicular drug delivery systems) and lipid particulate systems (consisting of lipospheres, solid lipid nanoparticles (SLNs), solid lipid microparticles (SLMs), nanostructured lipid carriers (NLCs) and Lipid drug conjugates (LDCs)), Polymeric Drug Delivery Systems consisting of polymer-drug conjugates (PDCs), polymeric nanoparticles, Enzyme based drug delivery systems, hydrogels, and other polymeric drug delivery systems comprised of microspheres, micelles or dendrimers and Viral vectors and other drug delivery systems consisting of cellular drug delivery systems like resealed erythrocytes, inorganic or metallic nanoparticle drug delivery systems and plasmid DNA vectors. Among these, the polymeric drug delivery systems segment accounted for the largest revenue in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027. Viral vectors and other drug delivery systems segment is the fastest emerging segment and is expected of growing at an exponential CAGR during the forecasted period. Lipid based drug delivery systems can be broadly classified as lipid emulsion drug delivery systems, lipid vesicular drug delivery systems and lipid particulate drug delivery systems. Among these, lipid particulate drug delivery systems segment is the largest and fastest emerging segment and is expected to grow at a mid single digit CAGR during the forecasted period. The most popular lipid vesicular drug delivery system, liposome’s global market is expected to grow at a high single digit CAGR from 2020 to 2027. The Polymeric Drug delivery systems market is segmented further into polymer-drug conjugates (PDC) and antibody drug conjugates (ADC), polymeric nanoparticles, enzyme based drug delivery systems, hydrogel drug delivery systems and other polymeric drug delivery systems comprised of dendrimers, micelles and microspheres. Among these, polymer drug conjugates segment holds the largest share of revenue in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027. Polymeric nanoparticles drug delivery segment is the fastest emerging segment and is expected of growing at a mid single digit CAGR from 2020 to 2027.
Based on the type of drug molecule being delivered, the drug delivery systems global market is classified into small molecule drug delivery systems and large molecule drug delivery systems. Among these, the small molecule drug delivery systems segment accounted for the largest revenue in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027. Large molecule drug delivery system segment is the fastest emerging segment and is expected of growing at a mid single digit CAGR from 2020 to 2027.
The drug delivery systems market, based on mechanism has been segmented into Rate Pre-Programmed Drug Delivery Systems, Targeted or site-specific Drug Delivery Systems and Stimuli responsive Drug Delivery Systems. Among these, the Rate Pre-programmed drug delivery systems segment accounted for the largest revenue in 2020 and is expected to grow at a mid single digit CAGR from 2020 to 2027. Targeted or site-specific drug delivery system segment is the fastest emerging segment and is expected of growing at a mid single digit CAGR during the forecasted period.
The Drug Delivery Systems global market based on application has been grouped into Oncology, Infectious diseases, Central Nervous System (CNS) Disorders, Metabolic Disorders, Autoimmune disorders, Respiratory diseases, Ophthalmology, Cardiovascular diseases and other applications consisting of Hematological diseases, Rare diseases and Genetic disorders, Hormonal disorders, Dermatological disorders and Wound Healing. Among these, Oncology segment is the largest and fastest emerging segment and is expected to grow at a mid single digit CAGR from 2020 to 2027 due to the persistently escalating cancer patients across the globe, elevated adoption rate of the large number of oncological drug products incorporated with drug delivery systems and the huge number of research studies being carried out for the development of safer, patient compliant and efficient oncological medications through the utilization of novel drug delivery systems.
The drug delivery systems global market is divided into four major geographies namely, North America, Europe, Asia Pacific (APAC) and Rest of World (ROW). The major share of the global market is occupied by North America in 2020 and is expected to grow at a mid single digit CAGR from 2020 to 2027 mainly due to persistently elevating chronic and infectious disease patient burden in the region, the ever inflating pharmaceutical market in the region and escalating demand for value-based therapeutics or prophylactics from the patient base of the region, elevating geriatric and pediatric patient pool with varied therapeutic requirements in the region, presence of huge number of pharma and biotech companies in the region and their increasing research and development spendings for the development of therapeutically efficient and safer medications through the utilization of drug delivery systems and the various strategies of pharma companies to economically maintain their market exclusivity through the utilization of novel drug delivery systems. Asia-Pacific (APAC) is the fastest emerging region and is expected of growing at a mid single digit CAGR during the forecasted period. The rapid market growth rate in this region is due to constantly elevating communicable and non-communicable disease patient pool in the region, the growing pharmaceutical market and the pharmaceutical and biotech formulation services sector in the region and the increasing awareness and demand for value-enhanced therapeutics or prophylactics from the patient base of the region, escalating geriatric and pediatric patient pool with varied therapeutic requirements in the region and growing economies of most of the countries in the region.
According to IQ4I analysis, the carrier linked prodrugs global market is expected to grow at a mid single digit CAGR from 2020 to 2027 due to the potential of carriers in realizing the envisioned therapeutic effects of the pharmaceutical agent. The nanotechnology enabled drug delivery systems global market is expected to grow at a mid single digit CAGR from 2020 to 2027 due to the potential of nano-drug delivery systems to improve the delivery and bioavailability of poorly water soluble therapeutics, to enhance the site-specific delivery of medications and to modify the release behavior of pharmaceutical agents.
The drug delivery enabling technology, product or service providers market is fragmented with the top players occupying minor share of the market and the remaining major share of the market being occupied by other players. The top five players occupy minor share of the market and the remaining major share of the market is occupied by other players. The top players in drug delivery enabling technology, product or service providers market are Thermo fisher Scientific Inc. (Patheon) (U.S.), Lonza Group Ltd. (Switzerland), Catalent, Inc. (U.S.), Merck KGaA (Germany), Evonik Industries (Germany), Halozyme Therapeutics Inc. (U.S.), Ligand Pharmaceuticals Incorporated (U.S.), Mitsubishi Chemical Holdings Corporation (Qualicaps CO. Ltd.) (Japan), Fujifilm Holdings Corporation (Japan), ACG (Associated Capsule Group) Worldwide (India) and others. The drug delivery system enhanced drug product providers market is consolidated with the few pharmaceutical players dominating and occupying major share of the market and the remaining minor share of the market being occupied by other players. The top five pharmaceutical players occupy majority of the market share and the remaining minority share of the market is occupied by other players. The top players in drug delivery enhanced product providers market are Johnson and Johnson (U.S.), Gilead Sciences Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Abbvie Inc. (U.S.), Takeda Pharmaceutical Company (Japan), Astellas Pharma (Japan), Biogen (U.S.), Pfizer Inc. (U.S.), Abbvie Inc. (U.S.), Amgen Inc. (U.S.), Novartis AG (Switzerland) and others. The drug delivery system enhanced product providers market is consolidated with the top five pharmaceutical players occupying 60.9% of the market share and the remaining 39.1% of the market being occupied by other players. The top players in drug delivery enhanced product providers market are Johnson and Johnson (U.S.), Gilead Sciences Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Abbvie Inc. (U.S.), Takeda Pharmaceutical Company (Japan), Astellas Pharma (Japan), Biogen (U.S.), Pfizer Inc. (U.S.), Abbvie Inc. (U.S.), Amgen Inc. (U.S.), Novartis AG (Switzerland) and others.
The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
- North America
- U.S.
- Rest of North America
- Europe
- Germany
- France
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Rest of APAC
- Rest of the World (RoW)
- Brazil
- Rest of LATAM
- Middle East and Africa
- 1 EXECUTIVE SUMMARY
- 2 INTRODUCTION
- 2.1 KEY TAKEAWAYS
- 2.2 SCOPE OF THE REPORT
- 2.3 REPORT DESCRIPTION
- 2.4 MARKETS COVERED
- 2.5 STAKEHOLDERS
- 2.6 RESEARCH METHODOLOGY
- 2.6.1 MARKET SIZE ESTIMATION
- 2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION
- 2.6.3 SECONDARY SOURCES
- 2.6.4 PRIMARY SOURCES
- 2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES
- 2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES
- 2.6.7 ASSUMPTIONS
- 3 MARKET ANALYSIS
- 3.1 INTRODUCTION
- 3.2 MARKET SEGMENTATION
- 3.3 FACTORS INFLUENCING MARKET
- 3.3.1 DRIVERS AND OPPORTUNITIES
- 3.3.1.1 NECESSITY OF DRUG DELIVERY SYSTEMS FOR ENHANCING THERAPEUTIC EFFICIENCY AND SAFETY PROFILE OF DRUGS
- 3.3.1.2 NEED FOR EFFICIENT BIOLOGICS DELIVERY SYSTEMS
- 3.3.1.3 INCREASING DEMAND FOR CONVENIENT DRUG DOSAGE FORMS FOR GERIATRIC AND PEDIATRIC POPULATION
- 3.3.1.4 INCREASING R&D EXPENDITURES OF INNOVATOR COMPANIES AND THE TREND OF PATENT PORTFOLIO EXPANSION
- 3.3.1.5 VAST DRUG DELIVERY TECHNOLOGY ENHANCED DRUG PRODUCT PIPELINE
- 3.3.1.6 ACQUISITIONS AND COLLABORATIONS TO OPEN AN ARRAY OF OPPORTUNITIES FOR THE MARKET TO FLOURISH
- 3.3.1.7 INCREASING PREVALENCE OF CHRONIC, COMMUNICABLE AND AUTOIMMUNE DISEASES
- 3.3.2 RESTRAINTS AND THREATS
- 3.3.2.1 HIGH COST OF DRUG DELIVERY SYSTEMS AND THE SUBSEQUENT DRUG PRODUCTS
- 3.3.2.2 ADVERSE EFFECTS OF DRUG DELIVERY SYSTEMS
- 3.3.2.3 INCONSISTENT AND EVOLVING GLOBAL REGULATORY LANDSCAPE
- 3.3.2.4 INEFFICIENCY OF TOXICITY TESTING AND EVALUATION STUDIES IN CHARACTERIZING NOVEL DRUG DELIVERY SYSTEMS
- 3.3.2.5 THREAT OF THERAPEUTIC MEDICAL DEVICES AND DRUG DELIVERY DEVICES
- 3.4 CARRIER LINKED PRODRUGS
- 3.5 PORTER’S FIVE FORCE ANALYSIS
- 3.5.1 THREAT OF NEW ENTRANTS
- 3.5.2 THREAT OF SUBSTITUTES
- 3.5.3 BARGAINING POWER OF SUPPLIERS
- 3.5.4 BARGAINING POWER OF BUYERS
- 3.5.5 COMPETITIVE RIVALRY
- 3.6 SUPPLY CHAIN ANALYSIS
- 3.7 NANOTECHNOLOGY ENABLED DRUG DELIVERY SYSTEMS
- 3.8 PATENT TRENDS
- 3.9 FUNDING SCENARIO
- 3.10 CLINICAL TRIALS
- 3.11 IMPACT OF COVID-19 ON DRUG DELIVERY SYSTEMS INDUSTRY
- 3.12 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
- 3.12.1 DRUG DELIVERY ENABLING TECHNOLOGY, PRODUCT OR SERVICE GLOBAL MARKET SHARE ANALYSIS
- 3.12.2 DRUG DELIVERY SYSTEM ENHANCED DRUG PRODUCT GLOBAL MARKET SHARE ANALYSIS
- 3.12.3 DRUG DELIVERY SYSTEMS COMPANY COMPARISON TABLE BY REVENUE, PRODUCT, PRODUCT TYPE, ROUTE OF ADMINISTRATION, PURPOSE
- 4 DRUG DELIVERY SYSTEMS GLOBAL MARKET, BY ROUTE OF ADMINISTRATION
- 4.1 INTRODUCTION
- 4.2 ORAL DRUG DELIVERY SYSTEMS
- 4.3 PARENTERAL DRUG DELIVERY SYSTEMS
- 4.4 TOPICAL DRUG DELIVERY SYSTEMS
- 4.5 PULMONARY OR INHALATION DRUG DELIVERY SYSTEMS
- 5 DRUG DELIVERY SYSTEMS GLOBAL MARKET, BY PRODUCT
- 5.1 INTRODUCTION
- 5.2 LIPID BASED DRUG DELIVERY SYSTEMS (LBDDS)
- 5.2.1 LIPID EMULSION DRUG DELIVERY SYSTEMS
- 5.2.2 LIPID VESICULAR DRUG DELIVERY SYSTEMS
- 5.2.2.1 LIPOSOME
- 5.2.3 LIPID PARTICULATE DRUG DELIVERY SYSTEMS
- 5.3 POLYMERIC DRUG DELIVERY SYSTEMS
- 5.3.1 POLYMER DRUG CONJUGATES AND ANTIBODY DRUG CONJUGATES DRUG DELIVERY SYSTEMS
- 5.3.2 POLYMERIC NANOPARTICLES DRUG DELIVERY SYSTEMS (NANOCAPSULES, NANOSPHERES, DRUG CONJUGATES)
- 5.3.3 ENZYME BASED DRUG DELIVERY SYSTEMS
- 5.3.4 HYDROGEL DRUG DELIVERY SYSTEMS
- 5.3.5 OTHER POLYMERIC DRUG DELIVERY SYSTEMS (MICROSPHERES, MICELLES, DENDRIMERS)
- 5.4 VIRAL VECTORS AND OTHER DRUG DELIVERY SYSTEMS
- 6 DRUG DELIVERY SYSTEMS GLOBAL MARKET, BY DRUG MOLECULE TYPE
- 6.1 INTRODUCTION
- 6.2 SMALL MOLECULE DRUG DELIVERY SYSTEMS
- 6.3 LARGE MOLECULE DRUG DELIVERY SYSTEMS
- 7 DRUG DELIVERY SYSTEMS GLOBAL MARKET, BY MECHANISM
- 7.1 INTRODUCTION
- 7.2 RATE PRE-PROGRAMMED DRUG DELIVERY SYSTEMS
- 7.3 TARGETED OR SITE-SPECIFIC DRUG DELIVERY SYSTEMS
- 7.4 STIMULI RESPONSIVE DRUG DELIVERY SYSTEMS
- 8 DRUG DELIVERY SYSTEMS GLOBAL MARKET, BY APPLICATION
- 8.1 INTRODUCTION
- 8.2 ONCOLOGY DRUG DELIVERY SYSTEMS
- 8.3 INFECTIOUS DISEASES DRUG DELIVERY SYSTEMS
- 8.4 CENTRAL NERVOUS SYSTEM DISORDERS DRUG DELIVERY SYSTEMS
- 8.5 AUTOIMMUNE DISEASES DRUG DELIVERY SYSTEMS
- 8.6 METABOLIC DISORDERS DRUG DELIVERY SYSTEMS
- 8.7 RESPIRATORY DISEASES DRUG DELIVERY SYSTEMS
- 8.8 OPHTHALMOLOGY DRUG DELIVERY SYSTEMS
- 8.9 CARDIOVASCULAR DRUG DELIVERY SYSTEMS
- 8.1 OTHER APPLICATIONS (HORMONAL DISORDERS, HEMATOLOGICAL DISORDERS, RARE DISEASES AND GENETIC DISEASES, DERMATOLOGICAL DISEASES, WOUND HEALING) DRUG DELIVERY SYSTEMS
- 9 REGIONAL ANALYSIS
- 9.1 INTRODUCTION
- 9.2 NORTH AMERICA
- 9.2.1 U.S.
- 9.2.2 REST OF NORTH AMERICA
- 9.3 EUROPE
- 9.3.1 GERMANY
- 9.3.2 FRANCE
- 9.3.3 ITALY
- 9.3.4 REST OF EUROPE
- 9.4 ASIA-PACIFIC
- 9.4.1 CHINA
- 9.4.2 JAPAN
- 9.4.3 INDIA
- 9.4.4 REST OF APAC
- 9.5 REST OF THE WORLD
- 9.5.1 BRAZIL
- 9.5.2 REST OF LATIN AMERICA (LATAM)
- 9.5.3 MIDDLE EAST AND AFRICA (MEA)
- 10 COMPETITIVE LANDSCAPE
- 10.1 INTRODUCTION
- 10.2 EXPANSION
- 10.3 PARTNERSHIPS, COLLABORATIONS AND AGREEMENTS
- 10.4 PRODUCT AND SERVICE LAUNCH
- 10.5 DDS ENHANCED PRODUCT APPROVAL
- 10.6 ACQUISITION
- 10.7 OTHER DEVELOPMENTS
- 11 MAJOR COMPANIES
- 11.1 ACG WORLDWIDE
- 11.1.1 OVERVIEW
- 11.1.2 FINANCIALS
- 11.1.3 PRODUCT PORTFOLIO
- 11.1.4 KEY DEVELOPMENTS
- 11.1.5 BUSINESS STRATEGY
- 11.1.6 SWOT ANALYSIS
- 11.2 CATALENT INC.
- 11.2.1 OVERVIEW
- 11.2.2 FINANCIALS
- 11.2.3 PRODUCT PORTFOLIO
- 11.2.4 KEY DEVELOPMENTS
- 11.2.5 BUSINESS STRATEGY
- 11.2.6 SWOT ANALYSIS
- 11.3 EVONIK INDUSTRIES AG
- 11.3.1 OVERVIEW
- 11.3.2 FINANCIALS
- 11.3.3 PRODUCT PORTFOLIO
- 11.3.4 KEY DEVELOPMENTS
- 11.3.5 BUSINESS STRATEGY
- 11.3.6 SWOT ANALYSIS
- 11.4 FUJIFILM HOLDINGS CORPORATION
- 11.4.1 OVERVIEW
- 11.4.2 FINANCIALS
- 11.4.3 PRODUCT PORTFOLIO
- 11.4.4 KEY DEVELOPMENTS
- 11.4.5 BUSINESS STRATEGY
- 11.4.6 SWOT ANALYSIS
- 11.5 HALOZYME THERAPEUTICS INC.
- 11.5.1 OVERVIEW
- 11.5.2 FINANCIALS
- 11.5.3 PRODUCT PORTFOLIO
- 11.5.4 KEY DEVELOPMENTS
- 11.5.5 BUSINESS STRATEGY
- 11.5.6 SWOT ANALYSIS
- 11.6 LIGAND PHARMACEUTICALS INCORPORATED
- 11.6.1 OVERVIEW
- 11.6.2 FINANCIALS
- 11.6.3 PRODUCT PORTFOLIO
- 11.6.4 KEY DEVELOPMENTS
- 11.6.5 BUSINESS STRATEGY
- 11.6.6 SWOT ANALYSIS
- 11.7 LONZA GROUP LTD.
- 11.7.1 OVERVIEW
- 11.7.2 FINANCIALS
- 11.7.3 PRODUCT PORTFOLIO
- 11.7.4 KEY DEVELOPMENTS
- 11.7.5 BUSINESS STRATEGY
- 11.7.6 SWOT ANALYSIS
- 11.8 MERCK KGAA
- 11.8.1 OVERVIEW
- 11.8.2 FINANCIALS
- 11.8.3 PRODUCT PORTFOLIO
- 11.8.4 KEY DEVELOPMENTS
- 11.8.5 BUSINESS STRATEGY
- 11.8.6 SWOT ANALYSIS
- 11.9 MITSUBHISHI CHEMICAL HOLDINGS CORPORATION
- 11.9.1 OVERVIEW
- 11.9.2 FINANCIALS
- 11.9.3 PRODUCT PORTFOLIO
- 11.9.4 KEY DEVELOPMENTS
- 11.9.5 BUSINESS STRATEGY
- 11.9.6 SWOT ANALYSIS
- 11.10 THERMO FISHER SCIENTIFIC INC.
- 11.10.1 OVERVIEW
- 11.10.2 FINANCIALS
- 11.10.3 PRODUCT PORTFOLIO
- 11.10.4 KEY DEVELOPMENTS
- 11.10.5 BUSINESS STRATEGY
- 11.10.6 SWOT ANALYSIS
- TABLE 1 DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 2 CARRIER LINKED PRODRUGS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 3 NANOTECHNOLOGY ENABLED DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 4 DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY ROUTE OF ADMINISTRATION, (2019-2027) ($MN)
- TABLE 5 ORAL DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 6 PARENTERAL DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 7 TOPICAL DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 8 PULMONARY OR INHALATION DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 9 DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
- TABLE 10 LIPID BASED DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
- TABLE 11 LIPID BASED DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 12 LIPID EMULSION DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 13 LIPOSOME GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 14 LIPID VESICULAR DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 15 LIPID PARTICULATE DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 16 POLYMERIC DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
- TABLE 17 POLYMERIC DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 18 POLYMER DRUG CONJUGATES AND ANTIBODY DRUG CONJUGATES DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 19 POLYMERIC NANOPARTICLES DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 20 ENZYME BASED DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 21 HYDROGEL DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 22 OTHER POLYMERIC DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 23 VIRAL VECTORS AND OTHER DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 24 DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY DRUG MOLECULE TYPE, (2019-2027) ($MN)
- TABLE 25 SMALL MOLECULE DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 26 LARGE MOLECULE DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 27 DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY MECHANISM, (2019-2027) ($MN)
- TABLE 28 RATE PRE-PROGRAMMED DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 29 TARGETED OR SITE-SPECIFIC DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 30 STIMULI RESPONSIVE DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 31 DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
- TABLE 32 ONCOLOGY DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 33 INFECTIOUS DISEASES DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 34 CENTRAL NERVOUS SYSTEM DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 35 AUTOIMMUNE DISEASES DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 36 METABOLIC DISORDERS DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 37 RESPIRATORY DISEASES DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 38 OPTHALMOLOGY DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 39 CARDIOVASCULAR DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 40 OTHER APPLICATIONS DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 41 DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 42 NORTH AMERICA DRUG DELIVERY SYSTEMS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, (2019-2027) ($MN)
- TABLE 43 NORTH AMERICA DRUG DELIVERY SYSTEMS MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
- TABLE 44 NORTH AMERICA LIPID BASED DRUG DELIVERY SYSTEMS MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
- TABLE 45 NORTH AMERICA POLYMERIC DRUG DELIVERY SYSTEMS MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
- TABLE 46 NORTH AMERICA DRUG DELIVERY SYSTEMS MARKET REVENUE, BY DRUG MOLECULE TYPE, (2019-2027) ($MN)
- TABLE 47 NORTH AMERICA DRUG DELIVERY SYSTEMS MARKET REVENUE, BY MECHANISM, (2019-2027) ($MN)
- TABLE 48 NORTH AMERICA DRUG DELIVERY SYSTEMS MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
- TABLE 49 NORTH AMERICA DRUG DELIVERY SYSTEMS MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
- TABLE 50 EUROPE DRUG DELIVERY SYSTEMS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, (2019-2027) ($MN)
- TABLE 51 EUROPE DRUG DELIVERY SYSTEMS MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
- TABLE 52 EUROPE LIPID BASED DRUG DELIVERY SYSTEMS MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
- TABLE 53 EUROPE POLYMERIC DRUG DELIVERY SYSTEMS MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
- TABLE 54 EUROPE DRUG DELIVERY SYSTEMS MARKET REVENUE, BY DRUG MOLECULE TYPE, (2019-2027) ($MN)
- TABLE 55 EUROPE DRUG DELIVERY SYSTEMS MARKET REVENUE, BY MECHANISM, (2019-2027) ($MN)
- TABLE 56 EUROPE DRUG DELIVERY SYSTEMS MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
- TABLE 57 EUROPE DRUG DELIVERY SYSTEMS MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
- TABLE 58 APAC DRUG DELIVERY SYSTEMS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, (2019-2027) ($MN)
- TABLE 59 APAC DRUG DELIVERY SYSTEMS MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
- TABLE 60 APAC LIPID BASED DRUG DELIVERY SYSTEMS MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
- TABLE 61 APAC POLYMERIC DRUG DELIVERY SYSTEMS MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
- TABLE 62 APAC DRUG DELIVERY SYSTEMS MARKET REVENUE, BY DRUG MOLECULE TYPE, (2019-2027) ($MN)
- TABLE 63 APAC DRUG DELIVERY SYSTEMS MARKET REVENUE, BY MECHANISM, (2019-2027) ($MN)
- TABLE 64 APAC DRUG DELIVERY SYSTEMS MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
- TABLE 65 APAC DRUG DELIVERY SYSTEMS MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
- TABLE 66 ROW DRUG DELIVERY SYSTEMS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, (2019-2027) ($MN)
- TABLE 67 ROW DRUG DELIVERY SYSTEMS MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
- TABLE 68 ROW LIPID BASED DRUG DELIVERY SYSTEMS MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
- TABLE 69 ROW POLYMERIC DRUG DELIVERY SYSTEMS MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
- TABLE 70 ROW DRUG DELIVERY SYSTEMS MARKET REVENUE, BY DRUG MOLECULE TYPE, (2019-2027) ($MN)
- TABLE 71 ROW DRUG DELIVERY SYSTEMS MARKET REVENUE, BY MECHANISM, (2019-2027) ($MN)
- TABLE 72 ROW DRUG DELIVERY SYSTEMS MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
- TABLE 73 ROW DRUG DELIVERY SYSTEMS MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
- TABLE 74 EXPANSION (2019 – 2021)
- TABLE 75 PARTNERSHIPS, COLLABORATION, AGREEMENTS (2019 – 2021)
- TABLE 76 PRODUCT AND SERVICE LAUNCH (2019 – 2021)
- TABLE 77 DDS ENHANCED PRODUCT APPROVAL (2019 - 2021)
- TABLE 78 ACQUISITION (2019 – 2021)
- TABLE 79 OTHER DEVELOPMENTS (2019 – 2021)
- TABLE 80 CATALENT INC.: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) ($MN)
- TABLE 81 CATALENT INC.: TOTAL REVENUE, BY SEGMENTS, (2019-2021) ($MN)
- TABLE 82 CATALENT INC.: SOFTGEL AND ORAL TECHNOLOGIES REVENUE, BY SUB-SEGMENTS, (2019-2021) ($MN)
- TABLE 83 CATALENT INC.: BIOLOGICS REVENUE, BY SUB-SEGMENTS, (2019-2021) ($MN)
- TABLE 84 CATALENT INC.: ORAL AND SPECIALTY DELIVERY REVENUE, BY SUB-SEGMENTS, (2019-2021) ($MN)
- TABLE 85 EVONIK INDUSTRIES AG: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) ($MN)
- TABLE 86 EVONIK INDUSTRIES AG: TOTAL REVENUE, BY SEGMENTS, (2019-2021) ($MN)
- TABLE 87 EVONIK INDUSTRIES AG: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) ($MN)
- TABLE 88 FUJIFILM HOLDINGS CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
- TABLE 89 FUJIFILM HOLDINGS CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
- TABLE 90 FUJIFILM HOLDINGS CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
- TABLE 91 HALOZYME THERAPEUTICS INC.: TOTAL REVENUE AND R&D EXPENSES (2019-2021) ($MN)
- TABLE 92 HALOZYME THERAPEUTICS: TOTAL REVENUE, BY SEGMENTS (2019-2021) ($MN)
- TABLE 93 HALOZYME THERAPEUTICS: TOTAL REVENUE, BY GEOGRAPHY (2019-2021) ($MN)
- TABLE 94 LIGAND PHARMACEUTICALS INC.: TOTAL REVENUE AND R&D EXPENSES (2019-2021) ($MN)
- TABLE 95 LIGAND PHARMACEUTICALS INC.: TOTAL REVENUE, BY SEGMENT, (2019-2021) ($MN)
- TABLE 96 LONZA GROUP LTD.: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
- TABLE 97 LONZA GROUP LTD.: TOTAL REVENUE, BY SEGMENTS (2018-2020) ($MN)
- TABLE 98 LONZA GROUP LTD.: LONZA PHARMA BIOTECH & NUTRITION REVENUE, BY SUB-SEGMENTS, (2018-2020) ($MN)
- TABLE 99 LONZA GROUP LTD.: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
- TABLE 100 MERCK KGAA: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) ($MN)
- TABLE 101 MERCK KGAA: TOTAL REVENUE, BY SEGMENTS (2019-2021) ($MN)
- TABLE 102 MERCK KGAA: LIFE SCIENCE REVENUE, BY SUB-SEGMENTS, (2019-2021) ($MN)
- TABLE 103 MERCK KGAA: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) ($MN)
- TABLE 104 MITSUBHISHI CHEMICAL HOLDINGS CORP.: TOTAL SALES AND R&D EXPENSES, (2018-2020) ($MN)
- TABLE 105 MITSUBHISHI CHEMICAL HOLDINGS CORP.: TOTAL SALES, BY SEGMENTS, (2018-2020) ($MN)
- TABLE 106 THERMO FISHER SCIENTIFIC: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) ($MN)
- TABLE 107 THERMO FISHER SCIENTIFIC: TOTAL REVENUE, BY SEGMENTS, (2019-2021) ($MN)
- TABLE 108 THERMO FISHER SCIENTIFIC: TOTAL REVENUE, BY PRODUCT TYPE, (2019-2021) ($MN)
- TABLE 109 THERMO FISHER SCIENTIFIC: TOTAL REVENUE, BY GEOGRAPHY, (2019-2020) ($MN)
- FIGURE 1 DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE AND SHARE, BY REGION (2019-2027) ($MN) AND 2020 (%)
- FIGURE 2 RESEARCH METHODOLOGY: DRUG DELIVERY SYSTEMS GLOBAL MARKET
- FIGURE 3 DRUG DELIVERY SYSTEMS GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
- FIGURE 4 DRUG DELIVERY SYSTEMS GLOBAL MARKET: FORECASTING MODEL
- FIGURE 5 DRUG DELIVERY SYSTEMS GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION
- FIGURE 6 DRUG DELIVERY SYSTEMS GLOBAL MARKET SEGMENTATION
- FIGURE 7 MARKET DYNAMICS
- FIGURE 8 DRUG DELIVERY SYSTEMS GLOBAL MARKET: PORTER’S ANALYSIS
- FIGURE 9 DRUG DELIVERY SYSTEMS : SUPPLY CHAIN ANALYSIS
- FIGURE 10 DRUG DELIVERY SYSTEMS GLOBAL MARKET: PATENT FILING BY MAJOR PLAYERS (2016-2021)
- FIGURE 11 DRUG DELIVERY SYSTEMS CLINICAL TRIAL ANALYSIS
- FIGURE 12 DRUG DELIVERY ENABLING TECHNOLOGY, PRODUCT OR SERVICE GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
- FIGURE 13 DRUG DELIVERY SYSTEM ENHANCED DRUG PRODUCT GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
- FIGURE 14 DRUG DELIVERY SYSTEMS GLOBAL MARKET SHARE, BY ROUTE OF ADMINISTRATION (2020 V/S 2027) (%)
- FIGURE 15 DRUG DELIVERY SYSTEMS GLOBAL MARKET SHARE, BY PRODUCT (2020 V/S 2027) (%)
- FIGURE 16 LIPID BASED DRUG DELIVERY SYSTEMS GLOBAL MARKET SHARE, BY PRODUCT TYPE (2020 V/S 2027) (%)
- FIGURE 17 POLYMERIC DRUG DELIVERY SYSTEMS GLOBAL MARKET SHARE, BY PRODUCT TYPE (2020 V/S 2027) (%)
- FIGURE 18 DRUG DELIVERY SYSTEMS GLOBAL MARKET SHARE, BY DRUG MOLECULE TYPE (2020 V/S 2027) (%)
- FIGURE 19 DRUG DELIVERY SYSTEMS GLOBAL MARKET SHARE, BY MECHANISM (2020 V/S 2027) (%)
- FIGURE 20 DRUG DELIVERY SYSTEMS GLOBAL MARKET SHARE, BY APPLICATION (2020) (%)
- FIGURE 21 RESPIRATORY DISEASES DRUG DELIVERY SYSTEMS, REGIONAL MARKET SHARE, (2020 V/S 2027) (%)
- FIGURE 22 DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN), CAGR (%)
- FIGURE 23 DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION AND BY COUNTRY, (2020) ($MN)
- FIGURE 24 NORTH AMERICA DRUG DELIVERY SYSTEMS MARKET SHARE, BY ROUTE OF ADMINISTRATION (2020 V/S 2027) (%)
- FIGURE 25 NORTH AMERICA DRUG DELIVERY SYSTEMS MARKET SHARE, BY PRODUCT (2020 V/S 2027) (%)
- FIGURE 26 NORTH AMERICA LIPID BASED DRUG DELIVERY SYSTEMS MARKET SHARE, BY PRODUCT TYPE (2020 V/S 2027) (%)
- FIGURE 27 NORTH AMERICA POLYMERIC DRUG DELIVERY SYSTEMS MARKET SHARE, BY PRODUCT TYPE (2020 V/S 2027) (%)
- FIGURE 28 NORTH AMERICA DRUG DELIVERY SYSTEMS MARKET SHARE, BY DRUG MOLECULE TYPE (2020 V/S 2027) (%)
- FIGURE 29 NORTH AMERICA DRUG DELIVERY SYSTEMS MARKET SHARE, BY MECHANISM (2020 V/S 2027) (%)
- FIGURE 30 NORTH AMERICA DRUG DELIVERY SYSTEMS MARKET SHARE, BY APPLICATION (2020) (%)
- FIGURE 31 NORTH AMERICA DRUG DELIVERY SYSTEMS MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
- FIGURE 32 U.S. DRUG DELIVERY SYSTEMS MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND PRODUCT (2020 V/S 2027) ($MN)
- FIGURE 33 U.S. DRUG DELIVERY SYSTEMS MARKET REVENUE, BY MECHANISM AND DRUG MOLECULE TYPE (2020 V/S 2027) ($MN)
- FIGURE 34 U.S. DRUG DELIVERY SYSTEMS MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 35 REST OF NORTH AMERICA DRUG DELIVERY SYSTEMS MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND PRODUCT (2020 V/S 2027) ($MN)
- FIGURE 36 REST OF NORTH AMERICA DRUG DELIVERY SYSTEMS MARKET REVENUE, BY MECHANISM AND DRUG MOLECULE TYPE (2020 V/S 2027) ($MN)
- FIGURE 37 REST OF NORTH AMERICA DRUG DELIVERY SYSTEMS MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 38 EUROPE DRUG DELIVERY SYSTEMS MARKET SHARE, BY ROUTE OF ADMINISTRATION (2020 V/S 2027) (%)
- FIGURE 39 EUROPE DRUG DELIVERY SYSTEMS MARKET SHARE, BY PRODUCT (2020 V/S 2027) (%)
- FIGURE 40 EUROPE LIPID BASED DRUG DELIVERY SYSTEMS MARKET SHARE, BY PRODUCT TYPE (2020 V/S 2027) (%)
- FIGURE 41 EUROPE POLYMERIC DRUG DELIVERY SYSTEMS MARKET SHARE, BY PRODUCT TYPE (2020 V/S 2027) (%)
- FIGURE 42 EUROPE DRUG DELIVERY SYSTEMS MARKET SHARE, BY DRUG MOLECULE TYPE (2020 V/S 2027) (%)
- FIGURE 43 EUROPE DRUG DELIVERY SYSTEMS MARKET SHARE, BY MECHANISM (2020 V/S 2027) (%)
- FIGURE 44 EUROPE DRUG DELIVERY SYSTEMS MARKET SHARE, BY APPLICATION (2020) (%)
- FIGURE 45 EUROPE DRUG DELIVERY SYSTEMS MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
- FIGURE 46 GERMANY DRUG DELIVERY SYSTEMS MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND PRODUCT (2020 V/S 2027) ($MN)
- FIGURE 47 GERMANY DRUG DELIVERY SYSTEMS MARKET REVENUE, BY MECHANISM AND DRUG MOLECULE TYPE (2020 V/S 2027) ($MN)
- FIGURE 48 GERMANY DRUG DELIVERY SYSTEMS MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 49 FRANCE DRUG DELIVERY SYSTEMS MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND PRODUCT (2020 V/S 2027) ($MN)
- FIGURE 50 FRANCE DRUG DELIVERY SYSTEMS MARKET REVENUE, BY MECHANISM AND DRUG MOLECULE TYPE (2020 V/S 2027) ($MN)
- FIGURE 51 FRANCE DRUG DELIVERY SYSTEMS MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 52 ITALY DRUG DELIVERY SYSTEMS MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND PRODUCT (2020 V/S 2027) ($MN)
- FIGURE 53 ITALY DRUG DELIVERY SYSTEMS MARKET REVENUE, BY MECHANISM AND DRUG MOLECULE TYPE (2020 V/S 2027) ($MN)
- FIGURE 54 ITALY DRUG DELIVERY SYSTEMS MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 55 REST OF EUROPE DRUG DELIVERY SYSTEMS MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND PRODUCT (2020 V/S 2027) ($MN)
- FIGURE 56 REST OF EUROPE DRUG DELIVERY SYSTEMS MARKET REVENUE, BY MECHANISM AND DRUG MOLECULE TYPE (2020 V/S 2027) ($MN)
- FIGURE 57 REST OF EUROPE DRUG DELIVERY SYSTEMS MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 58 APAC DRUG DELIVERY SYSTEMS MARKET SHARE, BY ROUTE OF ADMINISTRATION (2020 V/S 2027) (%)
- FIGURE 59 APAC DRUG DELIVERY SYSTEMS MARKET SHARE, BY PRODUCT (2020 V/S 2027) (%)
- FIGURE 60 APAC LIPID BASED DRUG DELIVERY SYSTEMS MARKET SHARE, BY PRODUCT TYPE (2020 V/S 2027) (%)
- FIGURE 61 APAC POLYMERIC DRUG DELIVERY SYSTEMS MARKET SHARE, BY PRODUCT TYPE (2020 V/S 2027) (%)
- FIGURE 62 APAC DRUG DELIVERY SYSTEMS MARKET SHARE, BY DRUG MOLECULE TYPE (2020 V/S 2027) (%)
- FIGURE 63 APAC DRUG DELIVERY SYSTEMS MARKET SHARE, BY MECHANISM (2020 V/S 2027) (%)
- FIGURE 64 APAC DRUG DELIVERY SYSTEMS MARKET SHARE, BY APPLICATION (2020) (%)
- FIGURE 65 APAC DRUG DELIVERY SYSTEMS MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
- FIGURE 66 CHINA DRUG DELIVERY SYSTEMS MARKET REVENUE, BY ROUTE OF ADMIMISTRATION AND PRODUCT (2020 V/S 2027) ($MN)
- FIGURE 67 CHINA DRUG DELIVERY SYSTEMS MARKET REVENUE, BY MECHANISM AND DRUG MOLECULE TYPE (2020 V/S 2027) ($MN)
- FIGURE 68 CHINA DRUG DELIVERY SYSTEMS MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 69 JAPAN DRUG DELIVERY SYSTEMS MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND PRODUCT (2020 V/S 2027) ($MN)
- FIGURE 70 JAPAN DRUG DELIVERY SYSTEMS MARKET REVENUE, BY MECHANISM AND DRUG MOLECULE TYPE (2020 V/S 2027) ($MN)
- FIGURE 71 JAPAN DRUG DELIVERY SYSTEMS MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 72 INDIA DRUG DELIVERY SYSTEMS MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND PRODUCT (2020 V/S 2027) ($MN)
- FIGURE 73 INDIA DRUG DELIVERY SYSTEMS MARKET REVENUE, BY MECHANISM AND DRUG MOLECULE TYPE (2020 V/S 2027) ($MN)
- FIGURE 74 INDIA DRUG DELIVERY SYSTEMS MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 75 REST OF APAC DRUG DELIVERY SYSTEMS MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND PRODUCT (2020 V/S 2027) ($MN)
- FIGURE 76 REST OF APAC DRUG DELIVERY SYSTEMS MARKET REVENUE, BY MECHANISM AND DRUG MOLECULE TYPE(2020 V/S 2027) ($MN)
- FIGURE 77 REST OF APAC DRUG DELIVERY SYSTEMS MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 78 ROW DRUG DELIVERY SYSTEMS MARKET SHARE, BY ROUTE OF ADMINISTRATION (2020 V/S 2027) (%)
- FIGURE 79 ROW DRUG DELIVERY SYSTEMS MARKET SHARE, BY PRODUCT (2020 V/S 2027) (%)
- FIGURE 80 ROW LIPID BASED DRUG DELIVERY SYSTEMS MARKET SHARE, BY PRODUCT TYPE (2020 V/S 2027) (%)
- FIGURE 81 ROW POLYMERIC DRUG DELIVERY SYSTEMS MARKET SHARE, BY PRODUCT TYPE (2020 V/S 2027) (%)
- FIGURE 82 ROW DRUG DELIVERY SYSTEMS MARKET SHARE, BY DRUG MOLECULE TYPE (2020 V/S 2027) (%)
- FIGURE 83 ROW DRUG DELIVERY SYSTEMS MARKET SHARE, BY MECHANISM (2020 V/S 2027) (%)
- FIGURE 84 ROW DRUG DELIVERY SYSTEMS MARKET SHARE, BY APPLICATION (2020) (%)
- FIGURE 85 ROW DRUG DELIVERY SYSTEMS MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
- FIGURE 86 BRAZIL DRUG DELIVERY SYSTEMS MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND PRODUCT (2020 V/S 2027) ($MN)
- FIGURE 87 BRAZIL DRUG DELIVERY SYSTEMS MARKET REVENUE, BY MECHANISM AND DRUG MOLECULE TYPE (2020 V/S 2027) ($MN)
- FIGURE 88 BRAZIL DRUG DELIVERY SYSTEMS MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 89 REST OF LATAM DRUG DELIVERY SYSTEMS MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND PRODUCT (2020 V/S 2027) ($MN)
- FIGURE 90 REST OF LATAM DRUG DELIVERY SYSTEMS MARKET REVENUE, BY MECHANISM AND DRUG MOLECULE TYPE (2020 V/S 2027) ($MN)
- FIGURE 91 REST OF LATAM DRUG DELIVERY SYSTEMS MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 92 MEA DRUG DELIVERY SYSTEMS MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND PRODUCT (2020 V/S 2027) ($MN)
- FIGURE 93 MEA DRUG DELIVERY SYSTEMS MARKET REVENUE, BY MECHANISM AND DRUG MOLECULE TYPE (2020 V/S 2027) ($MN)
- FIGURE 94 MEA DRUG DELIVERY SYSTEMS MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 95 KEY DEVELOPMENTS (2019 –2021)
- FIGURE 96 SWOT: ACG WORLDWIDE
- FIGURE 97 SWOT: CATALENT INC.
- FIGURE 98 SWOT: EVONIK INDUSTRIES AG
- FIGURE 99 SWOT: FUJIFILM HOLDINGS CORPORATION
- FIGURE 100 SWOT: HALOZYME THERAPEUTICS INC.
- FIGURE 101 SWOT: LIGAND PHARMACEUTICALS INCORPORATED
- FIGURE 102 SWOT: LONZA GROUP
- FIGURE 103 SWOT: MERCK KGAA
- FIGURE 104 SWOT: MITSUBHISHI CHEMICAL HOLDINGS CORPORATION
- FIGURE 105 SWOT: THERMO FISHER SCIENTIFIC INC.
- 1 ACG (Associated Capsule Group) Worldwide
- 2 Acuitas Therapeutics
- 3 Adare Pharmaceuticals (Orbis Biosciences)
- 4 Adocia
- 5 Alteogen Inc.
- 6 Altimmune Inc.
- 7 Altus Formulation Inc.
- 8 Amarin Technologies S.A.
- 9 Aptamer Group
- 10 Aquestive Therapeutics, Inc.
- 11 Arcturus Therapeutics Holdings Inc.
- 12 Arecor Ltd.
- 13 Ascendia Pharmaceuticals
- 14 BASF SE
- 15 Bharat Biotech
- 16 BioLingus AG
- 17 Bio-path Holdings Inc.
- 18 Biotts S.A.
- 19 Blafar Ltd.
- 20 Catalent, Inc.
- 21 Celares GmbH
- 22 Corium Inc.
- 23 Creative Biolabs, Inc.
- 24 CureVac AG
- 25 DelSiTech Ltd
- 26 Dendritech Inc.
- 27 DiNAQOR AG
- 28 EnGeneIC Ltd
- 29 EryDel SpA
- 30 Erytech Pharma S.A.
- 31 Eurofins (Eurofins Amatsigroup)
- 32 Evonik Industries
- 33 Evox Therapeutics Limited
- 34 Exelead Inc.
- 35 Feldan Therapeutics
- 36 ForDoz Pharma Corp.
- 37 FujiFilm Holdings Corporation
- 38 Halozyme Therapeutics, Inc.
- 39 Hydromer Inc.
- 40 i2O Therapeutics Inc.
- 41 ILIAS Biologics Inc.
- 42 Innocore Pharmaceuticals
- 43 InnoMedica Holding AG
- 44 IntelGenx Corp.
- 45 Interius Biotherapeutics Inc.
- 46 Intract Pharma Ltd
- 47 KemPharm, Inc.
- 48 Klaria Pharma Holding AB (WBC Drug Delivery Technologies)
- 49 Koru Life Science Ltd.
- 50 LDS (Lyotropic Delivery Systems) Biotech
- 51 Ligand Pharmaceuticals Incorporated
- 52 Lipidor AB
- 53 Lipocure Ltd
- 54 Lipomedix Pharmaceuticals
- 55 Liposoma BV
- 56 Lonza Group Ltd.
- 57 LTT Bio-Pharma Co-Ltd.
- 58 Lubrizol Life Science
- 59 Luye Life Sciences Group
- 60 MagForce AG
- 61 Magle Chemoswed AB
- 62 MDimune Inc.
- 63 Medesis Pharma SA
- 64 Merck KGaA
- 65 Mersana Therapeutics Inc.
- 66 MICELLAE Delivery Systems Inc.
- 67 Micropore Technologies
- 68 Midatech Pharma
- 69 Mitsubishi Chemical Holdings Corporation
- 70 Mymetics Corporation
- 71 N4 Pharma
- 72 Nanocomposix Inc.
- 73 Nextage Therapeutics
- 74 Novaliq GmbH
- 75 Oakwood Labs
- 76 Oramed Pharmaceuticals
- 77 Osmotica Pharmaceuticals plc
- 78 Oz Biosciences
- 79 Pacira Biosciences Inc.
- 80 Penlan Healthcare Ltd.
- 81 Piramal Group
- 82 PolyActiva Pty Ltd
- 83 PsiOxus Therapeutics Limited
- 84 Rani Therapeutics, LLC
- 85 Rubicon Research Private Limited
- 86 Serina Therapeutics, Inc.
- 87 Shanghai OMNI Pharmaceutical Technology Co. Ltd
- 88 SIRION Biotech
- 89 Sirnaomics, Inc.
- 90 Sitka Biopharma Inc.
- 91 Skyepharma Production SAS
- 92 Starpharma Holdings Limited
- 93 T&T Scientific Corporation
- 94 Taiwan Liposome Company Ltd.
- 95 TALLC Corporation Inc.
- 96 Tenaya Therapeutics
- 97 TFF Pharmaceuticals, Inc.
- 98 Thermo fisher Scientific Inc.
- 99 Tyndall Formulation Services, LLC.
- 100 Vaxart Inc.
- 101 Vect-Horus
- 102 ViGeneron GmbH
- 103 Vivera Pharmaceuticals Inc.
- 104 W. R. Grace & Co.